Home
MRUS
MRUS News

Latest Merus N.V. (MRUS) News on February 22, 2025

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Zacks

2 days ago

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

MT Newswires

4 days ago

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

GlobeNewswire

4 days ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

GlobeNewswire

9 days ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

MT Newswires

9 days ago

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MT Newswires

15 days ago

Wells Fargo Initiates Merus at Overweight With $91 Price Target

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

17 days ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Insider Monkey

a month ago

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Simply Wall St.

a month ago

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

MT Newswires

a month ago

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewswire

a month ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Insider Monkey

a month ago

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

MT Newswires

2 months ago

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewswire

2 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Insider Monkey

2 months ago

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

GlobeNewswire

3 months ago

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Benzinga

3 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Clinical Trials Arena

3 months ago

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

MT Newswires

3 months ago

Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

GlobeNewswire

3 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus price target lowered to $109 from $111 at Guggenheim

TipRanks

3 months ago

Merus price target lowered to $109 from $111 at Guggenheim

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

Benzinga

3 months ago

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

MT Newswires

3 months ago

Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

3 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

GlobeNewswire

3 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey

3 months ago

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

3 months ago

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Insider Monkey

3 months ago

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

Merus to Present at Upcoming Investor Conferences

MT Newswires

4 months ago

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

Merus Receives FDA extension of PDUFA for zenocutuzumab

GlobeNewswire

4 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

4 months ago

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

4 months ago

Merus's Shares Dip After Reporting Wider-Than-Expected Q3 Net Loss

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

4 months ago

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

GlobeNewswire

4 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

MT Newswires

4 months ago

UBS Initiates Merus With Buy Rating, $72 Price Target

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

Simply Wall St.

4 months ago

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Zacks

4 months ago

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

GlobeNewswire

5 months ago

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Insider Monkey

5 months ago

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

GlobeNewswire

5 months ago

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

5 months ago

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

Insider Monkey

6 months ago

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

MT Newswires

6 months ago

Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Simply Wall St.

6 months ago

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

GlobeNewswire

7 months ago

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Zacks

7 months ago

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire

7 months ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks

7 months ago

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

7 months ago

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

GlobeNewswire

7 months ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

Simply Wall St.

7 months ago

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

MT Newswires

7 months ago

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

GlobeNewswire

7 months ago

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

MT Newswires

8 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

8 months ago

Merus Names New Chief Medical Officer

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire

8 months ago

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

MT Newswires

8 months ago

Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating

MT Newswires

8 months ago

Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing

MT Newswires

9 months ago

BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating

MT Newswires

9 months ago

Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating

MT Newswires

9 months ago

Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire

9 months ago

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

MT Newswires

9 months ago

Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

GlobeNewswire

9 months ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

MT Newswires

9 months ago

Merus Prices $400.2 Million Public Share Offering

Merus Announces Pricing of Upsized Public Offering of Common Shares

GlobeNewswire

9 months ago

Merus Announces Pricing of Upsized Public Offering of Common Shares

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

Simply Wall St.

9 months ago

These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat

MT Newswires

9 months ago

BofA Securities Adjusts Merus Price Target to $80 From $61, Maintains Buy Rating

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire

9 months ago

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

MT Newswires

9 months ago

HC Wainwright Adjusts Price Target on Merus to $85 From $65, Maintains Buy Rating

MT Newswires

9 months ago

Merus Launches $300 Million Stock Offering

Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire

9 months ago

Merus N.V. Announces Proposed Public Offering of Common Shares

MT Newswires

9 months ago

Guggenheim Adjusts Merus Price Target to $93 From $57, Maintains Buy Rating

MT Newswires

9 months ago

BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating

MT Newswires

9 months ago

Stifel Adjusts Price Target on Merus to $90 From $65, Maintains Buy Rating

GlobeNewswire

9 months ago

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Zacks

9 months ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Investor's Business Daily

9 months ago

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

Benzinga

9 months ago

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

MT Newswires

9 months ago

Top Midday Gainers

Merus Clears Wall Street's Bar With Cancer Data

Barrons.com

9 months ago

Merus Clears Wall Street's Bar With Cancer Data

MT Newswires

9 months ago

Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Barrons.com

9 months ago

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

MT Newswires

9 months ago

BofA Adjusts Price Target on Merus to $61 From $52, Maintains Buy Rating

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Pharmaceutical Technology

9 months ago

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

MT Newswires

9 months ago

Top Premarket Gainers

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

GlobeNewswire

9 months ago

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire

9 months ago

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

MT Newswires

9 months ago

Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

GlobeNewswire

9 months ago

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

9 months ago

Merus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame

Simply Wall St.

9 months ago

Investors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blame

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire

9 months ago

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

GlobeNewswire

10 months ago

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Zacks

10 months ago

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

Zacks

10 months ago

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know

Zacks

10 months ago

Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

GlobeNewswire

10 months ago

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

GlobeNewswire

10 months ago

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Share on Social Networks: